This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 3 of 593

Biotech Stock Mailbag: Biotech Bull So Insanely Good It Will Make You Forget Week's Pain

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

08:31AM 05/01/15

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales

By Adam Feuerstein

Sales of MannKind's inhaled insulin Afrezza totaled €1 million in the first quarter of its commercial launch.

06:51AM 04/30/15

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings

By Adam Feuerstein

Sanofi reports first-quarter earnings on Thursday morning, but it's unclear if sales of the recently launched inhaled insulin medication Afrezza will be disclosed.

01:18PM 04/29/15

Ariad Pharma CEO 'Retires' in Settlement With Activist Hedge Fund

By Adam Feuerstein

Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.

09:01AM 04/29/15

Here's What's Next as BioMarin Moves Closer to Duchenne Drug Approval

By Adam Feuerstein

Will the FDA bring together DMD experts for a single meeting to review both BioMarin's drisapersen and Sarepta's eteplirsen, or will two separate meetings be scheduled?

12:09PM 04/28/15

First-Quarter Sales of Bristol-Myers' Cancer Immunotherapy Drug Miss Street Forecast

By Adam Feuerstein

Overall, Bristol sales in the March quarter were $4 billion, a 6% increase from one year ago and higher than consensus.

08:11AM 04/28/15

Merck Sales of New Cancer Immunotherapy Top Street Estimates

By Adam Feuerstein

On an adjusted basis, Merck reported first quarter earnings per share of 85 cents, topping the Street consensus of 74 cents per share.

07:51AM 04/28/15

Gene Therapy Stocks on Watch Following Failure of Celladon's Heart Failure Trial

By Adam Feuerstein

Will the failure of Celladon's Mydicar gene therapy bring other high-flying gene therapy stocks down to Earth?

08:45PM 04/26/15

Catalyst Pharma Competitor Surprises With Positive Orphan Disease Drug Study Results

By Adam Feuerstein

Catalyst and Jacobus Pharma are racing to secure FDA approval for a drug to treat a rare muscle-wasting disease.

12:05PM 04/24/15

Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug

By Adam Feuerstein

None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.

09:12AM 04/24/15

Page 3 of 593

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,095.89 -67.10 -0.37%
S&P 500 2,118.54 -4.94 -0.23%
NASDAQ 5,093.0030 -13.59 -0.27%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs